Covid Inquiry: Mistake not to consider range of pandemics – David Cameron
David Cameron says “group think” meant government focused on flu pandemics, rather than other diseases.
Similar Posts
Growing skincare use by children is dangerous, say dermatologists
Dermatologists say products with ingredients potentially harmful to children are growing popular.
Arkansas man receives world’s first eye transplant
Aaron James lost his nose, mouth and left eye in a work-related accident. Surgeons in New York successfully performed the reconstruction that included a whole-eye implant. His vision was not restored, but the first-of-its-kind procedure may help advance transplant medicine. “If some form of vision restoration occurred, it would be wonderful, but… the goal was…
Ovarian cancer treatment on fast track for FDA approval as chemo alternatives emerge: ‘We’re making progress’
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the…
New SC company uses telemedicine to offer health care to restaurant, hospitality workers
Neel Ghoshal was 13 years old when his life changed. Born in 1978 to Sam and Pritha Ghoshal, who immigrated from India eight years earlier in pursuit of the American Dream, Neel grew up in the Northeast. There were moments of struggle but life was good in the New York City area, where his father…
Brain tumor patient plays guitar during surgery: ‘This is wild’
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
These 4 anti-obesity drug stocks could soar, Berenberg says
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs,…